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Abstract 
We report the epidemiological and clinical features of the first outbreak of KPC 
producing Klebsiella pneumoniae (KPC-KP) type 2 in Switzerland. The outbreak took 
place in the medical ICU of our tertiary care hospital and affected three severely ill 
patients. After implementation of strict infection control measures, no further 
colonisations could be detected by screening of exposed patients. Successful 
treatment consisted of a triple therapy of meropenem, colistin and tigecycline. 
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Text 
Introduction 
Within the last decade, carbapenem-resistant Enterobacteriaceae (CRE) have 
become a major global threat [1,2]. One of the most common CRE, carbapenemase-
producing Klebsiella pneumoniae (KPC-KP), was first described 1996 in Eastern 
USA and has since spread globally [2,3]. Prevalence of KPC-KP in Europe is 
increasing, although rates vary considerably between countries [1]. A north-south 
gradient can be seen with KPC-KP being endemic in Italy, Greece and Israel [1]. A 
recent survey from Italy reported several hospital outbreaks and countrywide 
dissemination of KPC-KP [4,5]. In many European countries with low KPC 
prevalence, outbreaks have been linked to patients transferred from endemic regions 
[1,6].  
In Switzerland, the prevalence of KPC-KP is unknown, as only data on the number of 
isolates with elevated minimal inhibitory concentrations (MIC) for carbapenems are 
available [7]. The first description of a KPC producer was a KPC-2 K. pneumoniae 
isolate in urine and sputum samples from a patient transferred from Sicily (Italy) to 
Neuchâtel (Switzerland) in 2011 [8]. Subsequently, four unrelated cases of KPC-2 
and KPC-3 K. pneumoniae were reported from the University Hospital of Basel. All 
four cases were related to endemic countries [9]. 
We report the first outbreak of KPC-KP in Switzerland, its epidemiological and clinical 
features as well as the infection control measures implemented during the outbreak 
period.  
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Methods 
Setting 
Our institution is a 700-bed tertiary care hospital in Eastern Switzerland, treating 
approximately 33’000 inpatients annually. Supposed transmission of KPC-KP took 
place in the 12-bed medical intensive care unit (MICU) between February and April 
2013. In 2012, a total of 2’108 patients were hospitalized on the ward accounting for 
5870 patient-, 1610 ventilation- and 257 dialysis-days. At the time of the outbreak, an 
admission screening only for MRSA was performed for patients at risk [10].  
Microbiology 
Aerobic and anaerobic blood cultures were incubated in the Bactec™ FX 
(BDBioscience, San Jose, CA) according to the manufacturer instructions. Positive 
blood cultures and samples of the lower respiratory tract were processed according 
to standard procedures [11,12].  
Since selective culture media for KPC-KP were not available in our laboratory during 
the outbreak screening was done as follows. Nasal, pharyngeal, rectal, axillary and 
inguinal screening swabs (Copan, Brescia, Italy) were inoculated on MacConkey 
agar plates (BD Bioscience, San Jose, CA) for 24 and 48 hours. Growing colonies of 
different morphotypes were identified by MALDI-TOF (Bruker, Billerica, MA) and 
susceptibility testing was performed with the BD Phoenix™-100 (BD Bioscience, San 
Jose, CA) system according to CLSI guidelines [13]. Multiresistant K. pneumoniae 
with elevated MICs for carbapenems were further tested with Etest® containing 
imipenem (with and without EDTA), double disk synergy test with boronic acid as well 
as with the modified Hodge test [9,13]. MICs of colistin and tigecycline were 
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determined with Etest® (BioMérieux, Marcy-l’Etoile, France). KPC-specific 
conventional polymerase chain reaction (PCR) was followed by direct sequencing as 
previously described [9]. Molecular typing of KPC-KP was done using PFGE using 
restriction endonuclease XbaI according to Babouee et al. [14], with the exception of 
calculating percent similarities based on the Pearson instead of the Dice coefficient. 
PFGE patterns were analysed using software package GelCompar II, version 5.10 
(Applied Maths NV, Sint-Martens-Latem, Belgium).  
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Results 
Outbreak description and epidemiological investigation 
In case 1, KPC-KP was detected in a blood culture on March 17th. On the same day, 
case 2 revealed a KPC-KP positive bronchial secretion. Therefore an outbreak 
investigation according to international guidelines was initiated [15]. 
As cases 1 and 2 were roommates in the MICU from March 7th to March 11th, this 
ward was identified as putative place of transmission and screening of patients at risk 
was performed. Active screening revealed a third patient (case 3) on March 21th with 
KPC-KP positive screening samples (Fig 1).  
All patients hospitalised for more than three days were planned to undergo 
screening, if they stayed on the MICU between February 19th and April 23th. 
Screening was repeated every 7 days for patients in the MICU. If patients were 
discharged from the MICU, two additional screenings 7 days apart were planned.  
Case one was also hospitalised on the hemato-oncology ward during the outbreak 
period. Since he always stayed in a single room and hand hygiene adherence was 
over 80%, no further screening was done in the hemato-oncology ward.  
36 patients were planned to undergo screening. 21 completed the screening with at 
least two screenings being negative (one patient with 6 screenings, 6 patients with 3 
screenings and 14 patients with 2 screenings). 13 patients had incomplete 
screenings, with 7 patients having only one negative screening and 6 patients having 
been discharged from our institution before start of screening. Patients with 
incomplete screening were labelled in our electronic alert system to ensure screening 
at rehospitalisation. Two patients died. One passed away after unsuccessful 
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resuscitation following cardiac arrest. The second patient was discharged from the 
MICU to a rehabilitation clinic after treatment of cardiogenic shock. He was 
readmitted to another hospital because of hematothorax and died of 
bronchopneumonia. KPC-KP as the cause of the pneumonia can not be excluded. 
Both patients were not screened.  
Infection control measures and interventions 
Cases were put under contact precautions and patient cohorting was initiated. Staff 
cohorting was arranged but could not be strictly maintained. At time of outbreak 
detection, all rooms, surfaces and devices were disinfected with a quarternary 
ammonium-based formulation. This procedure was repeated 3 weeks after outbreak 
detection. In addition, disinfection was repeated each time an isolated patient was 
discharged from the MICU. Hand hygiene adherence and hygiene behaviour was 
observed by infection control specialists and direct feedback was given to the 
healthcare workers. During the outbreak, hand hygiene adherence according to 
WHO-guidelines [16] was 82% (243 opportunities observed). 
Patients transferred to other units in our institution were not preemptively contact 
isolated, but health care workers, patients and family members were encouraged to 
adhere to standard precautions, especially to hand hygiene.  
For patients at risk having been discharged from our institution before start of the 
screening, health care workers involved in subsequent patient care were informed.  
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Microbiological investigations 
The isolated strains from cases 1, 2 and 3 were sent to the reference laboratory in 
Basel, where phenotypic and molecular methods confirmed KPC-KP. Genotyping 
after sequencing exhibited betalactamase (bla) KPC-2 gene. Additionally, PFGE of 
the three K. pneumoniae strains showed very similar fingerprints indicating clonal 
identity (Fig 2). 
Description of cases (Table 1) 
Case 1 
Case 1, a 54-year old man with multiple myeloma, was hospitalised on February 25th 
for administration of high dose chemotherapy. He was transferred to the MICU on 
March 7th because of aplasia and bilateral pneumonia with persistent fever spikes. 
After being treated with piperacillin/tazobactam he clinically improved and could be 
transferred back to the hematoncology unit on March 11th. Three days later the 
patient again developed fever. Blood cultures from March 17th grew KPC-KP and 
antibiotic therapy was switched to meropenem and tigecyclin. Assuming catheter-
related bloodstream infection, the central line was removed and the catheter tip 
cultured (no growth). The patient subsequently recovered quickly and antibiotic 
therapy was stopped on the day of hospital discharge on March 29th. On April 4th 
however, he had to be readmitted due to pneumonia. KPC-KP was again isolated 
from the bronchoalveolar lavage (BAL) and meropenem, tigecycline and colistin were 
administered for 12 days. The patient was finally discharged on April 16th. 
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Case 2 
Case 2, a 67-year old Swiss male spending his vacation in Italy, had been 
hospitalised in Calabria from the 17th to 19th of February because of bilateral 
pneumonia. Antibiotic therapy with ampicillin/sulbactam and levofloxacin was 
initiated. On February 19th, the patient was transferred to our MICU. 
Upon arrival at our hospital, antibiotic therapy was changed to 
piperacillin/tazobactam and clarithomycin. Because of worsening of the respiratory 
situation, extracorporeal membrane oxygenation (ECMO) was installed. A multiplex-
PCR of the BAL was positive for Influenza A and therapy with oseltamivir was 
started. The patient was not put on droplet isolation because he was mechanically 
ventilated at that time. Piperacillin/tazobactam was switched to imipenem. The 
cardiopulmonary situation slowly improved and the ECMO could be removed on 
March 14th. Because of an inguinal deep vein thrombosis and at the same time 
bleeding complications in the nasopharynx, an inferior V. cava (IVC) filter was 
installed. Because of recurrent fever all intravascular catheters were exchanged on 
March 15th and cultures of the central catheter tip showed KPC-KP. The same 
microorganism could be detected in a BAL performed on March 17th because of 
respiratory deterioration. Antibiotic therapy was switched to meropenem, colistin and 
tigecycline assuming ventilator-associated pneumonia. The patient recovered and 
could finally be extubated on April 7th. After removal of the IVC filter, the patient was 
transferred to another hospital on April 15th. 
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Case 3 
Case 3, a 39-year old man, was initially admitted to a hospital in Austria because of 
sepsis and bilateral pneumonia on March 9th. Due to respiratory deterioration of the 
intubated patient, ECMO was installed and the patient was transferred to our MICU.  
Influenza B and S. aureus could be isolated from the patient’s sputum and therapy 
with oseltamivir and amoxicillin/clavulanate was begun. Due to the Pantone-
Valentine-Leukocidine-(PVL)-producing S. aureus, clindamycin (for 14 days) and 
intravenous immunglobulins (for 3 days) were administered. No droplet isolation was 
installed because the patient was on mechanical ventilation. The patient remained 
under ECMO until March 24th. He exhibited multiple complications of sepsis: because 
of acral necrosis due to microvascular derangements, both feet and 9 fingers had to 
be amputated in the course of hospitalisation. Short-term agranulocytosis was 
probably related to severe sepsis (including PVL) and/or multiple medications. 
Furthermore, the patient developed renal failure and was dependent on renal 
replacement therapy until transferal. In the patient screening from March 21th, swab 
samples of the patient’s skin, pharynx and rectum were positive for KPC-KP. 
Antibiotic therapy was first switched to meropenem. Tigecyclin and colistin were 
added on March 26th due to suspected VAP with secondary KPC-KP bacteremia. The 
patient could finally be extubated and was transferred to another hospital on April 
23th. 
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Discussion 
Outbreak and epidemiology 
To the best of our knowledge this is the first published outbreak with KPC-KP in 
Switzerland confirmed by PFGE-identical strains. 
We postulate case 2, who was transferred from an Italian hospital, being the index 
patient of the described outbreak. This hypothesis is corroborated by looking at the 
epidemiology of KPC-KP in Europe. Italy is one of the few European countries where 
CRE are considered to be endemic, especially KPC-2 and KPC-3 producing K. 
pneumonia [1,4,5]. Many cases and outbreaks of CRE in other countries have been 
attributed to patient transfers from Italy [6,9].  
Case 3 was admitted to the ICU after first isolation of the bacterium and is therefore 
excluded as possible source of the outbreak. Case 1 was not hospitalised abroad 
within the 12 months preceding the outbreak, which makes him less likely to be the 
index patient.  
Infection control measures 
Since the gastrointestinal tract is the most common human reservoir, KPC-KP 
acquisition by ingestion is likely [17]. Depending on the gastrointestinal flora and 
antibiotic consumption, gastrointestinal colonisation is transient or permanent. During 
the time of gastrointestinal carriage, shedding and transmission to other patients is 
possible [17]. Even though this mechanism may account for transmission in the 
community setting, transmission of KPC-KP in western countries is almost 
exclusively seen in hospitals [17]. Although never proven in health care settings, 
transmission is assumed to happen through contact between patients and personnel. 
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Fortunately, our outbreak was rapidly controlled with rigorous hand hygiene, contact 
precautions with cohorting and surface disinfection. However, screening of exposed 
patients was incomplete and follow-up of discharged patients was difficult. One sixth 
of the patients at risk were not screened because of early discharge to another 
institution. They could potentially serve as reservoir for KPC-KP and spread the 
bacteria within the community or within health care institutions in case of 
rehospitalisation. Electronic patient labelling might help to identify these patients in 
case of readmission to our institution. Admission to other institutions however would 
go undetected as electronic patient systems are not connected between different 
hospitals in our region. Having organisational problems in the regional setting shows 
how complicated it may be to obtain and provide information about outbreaks and 
local epidemiology on an international level. Therefore better regional, national and 
international collaboration is needed as already proposed by the ESCMID Expert 
Group on acquired carbapenemases 2010 [18].  
Given the absence of KPC-KP in our institution before this outbreak, our laboratory 
was not prepared to do patient screenings for KPC-KP. Therefore screenings during 
the outbreak were done without selective culture media for KPC-KP, resulting in a 
lower screening sensitivity. After control of the outbreak, a screening program for 
patients at risk for CRE has been implemented in our institution using selective 
culture media. Up to date, KPC-KP has not been detected in our hospital since the 
outbreak, neither in clinical nor in screening samples. In light of our experiences, we 
recommend initiation of appropriate screening methods for CRE in every hospital. 
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Clinical aspects 
All of our patients exhibited risk factors for the acquisition of K. pneumonia. Whereas 
case 1 was immunocompromised due to high dose chemotherapy, all three patients 
suffered of severe infections and were therefore treated with broad-spectrum 
antibiotics before infection with KPC-KP. In addition, cases 2 and 3 had severe 
sepsis, being itself a state of immunosuppression [19], and had a prolonged ICU 
stay. Moreover, these two patients were on ECMO and on mechanical ventilation at 
time of KPC-KP isolation, both factors contributing to the increased susceptibility to 
nosocomial pathogens [20].   
Data on treatment of CRE are scarce. As has been shown in vitro, carbapenems 
seem to have a synergistic effect given together with colistin or tigecycline despite 
the presence of carbapenemase [21,22]. Our patients were treated with a 
combination therapy consisting of meropenem, tigecycline and colistin. In a 
retrospective study analysing 125 cases of bloodstream infections (BSI) with KPC 
producing bacteria, this combination therapy was associated with a decreased 
mortality (34 vs 54%) compared to patients with monotherapy [23]. Similar results 
have been published by others [24,25]. In addition, development of resistance has 
been documented under monotherapy, especially for colistin [26]. Combination 
therapy against KPC-KP should therefore be the treatment of choice until further data 
based on prospective randomized trials are available. 
Conclusion 
Our report describes a KPC-2 outbreak in Switzerland following a patient transfer 
from Italy and its containment by application of rigorous infection control measures. 
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Infections in the three affected individuals were successfully treated with a triple 
therapy consisting of meropenem, colistin and tigecycline.  
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Figures 
Fig. 1 Timeline of the outbreak  
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Fig. 2 Pulsed-field gel electrophoresis (PFGE) using XbaI of the three KPC-2 K. 
pneumoniae isolates compared with an unrelated KPC-2 K. pneumoniae strain 
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Tables 
Table 1: Outbreak of KPC-KP, February to April 2013: Characteristics of involved 
patients (n=3), all having been treated with meropenem, colistin and tigecyclin  
Case Underlying condition 
Reason for 
MICU-
admission 
Hospita- 
lisation 
abroad1 
Device2 
KPC-KP 
positive 
samples 
KPC-KP 
infection  
Duration of 
antibiotic 
treatment  
Survival
3 
1 
Multiple 
myeloma, 
high dose 
chemotherapy 
Aplasia and 
bilateral 
pneumonia (no 
microorganism) 
no CL Blood, BAL 
CRBSI 
assumed, 
HAP  
12 days yes 
2  None 
Bilateral 
pneumonia 
(Influenza A) 
Italy 
ECMO, 
MV, IVC 
filter, CL 
Tracheo-
bronchial, 
CL4 
VAP 4 weeks yes 
3 None 
Bilateral 
pneumonia 
(Influenza B, 
MSSA) 
Austria 
ECMO, 
MV, 
cvvHD, 
CL 
Skin, 
pharynx, 
rectum, 
blood, 
BAL 
VAP with 
secondary 
BSI assumed 
4 weeks yes 
MICU=medical intensive care unit, KPC-KP=KPC-producing Klebsiella pneumoniae, CL=central line, CRBSI=catheter-
related blood stream infection, HAP=hospital acquired pneumonia, BAL=bronchoalveolar lavage, ECMO=extracorporal 
membrane oxygenation, MV=mechanical ventilation, IVC=inferior vena cava, VAP=ventilator associated pneumonia, 
MSSA=methicillin sensitive Staphylococcus aureus, cvvHDF=continuous veno-venous hemofiltration, BSI=blood stream 
infection 
 
1 within 30 days before MICU admission, 2 at time of KPC-KP detection, 3 at 30 days after KPC-KP detection, 4 i.e. cultured 
catheter tip 
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